Table 2.

Comorbidities and Other Medication Use in Orthostatic Hypotension Drug User

Comorbidities (%) Group	Fludrocortisone (N=1324)	Midodrine (n=797)	P Value
Cardiovascular conditions
Myocardial infarction	11.9	14.4	0.096
Obstructive coronary artery diseasea	37.3	44.2	0.002
Congestive heart failureb	22	29	<0.001
Hypertensionb	57	65.4	<0.001
Peripheral artery disease, etc	10.5	12.9	0.089
Atrial fibrillation	14.7	16.4	0.290
Arrhythmiasb	32.3	39.4	<0.001
Endocrine conditions
Obesity (or weight gain)	4.1	5.5	0.130
Hyperlipidemia/lipid disorderb	24.7	31.7	<0.001
Diabetes mellitusb	34.4	41.8	<0.001
Thyroid disease	15.2	13.7	0.340
Neurological conditions
Syncope, faintinga	37.7	43.3	0.011
Stroke/transient ischemic attack	14.6	12	0.100
Peripheral neuropathy	14	14.1	1.000
Parkinson's disease	8.2	7.2	0.400
Autonomic neuropathy	6.1	7.3	0.300
Multiple system atrophy	4.2	3.8	0.600
Others
Cigarette smokinga	18	22	0.025
Dementia	14	14.6	0.710
Cancer	19	21	0.280
COPD	38.7	40.3	0.460
Depressiona	24.5	29.6	0.009
Excessive alcohol consumption	4	3.9	0.900
Musculoskeletal conditions
Osteoporosis	9.5	7.4	0.095
History of fracture	11.6	11.9	0.800
Joint disease (arthritis and arthrosis)	24.8	26.7	0.340
Medications
Sympatholytic agents	4.2	5.1	0.330
Direct‐acting vasodilators	1.4	2	0.320
β‐Blockersb	26.1	36.3	<0.001
Calcium channel blocker	19.9	21.1	0.500
ACE inhibitors and ARBsa	31.2	36.3	0.016
α‐Adrenoreceptor‐blocking drugs	3	2.6	0.610
Diuretics aloneb	37.2	46.8	<0.001
Nitrates	21.5	21.7	0.890
Antidiabeticsa	26.1	31.5	0.007
Narcoticsa	57.7	64.2	0.003
Antidepressantsa	53.9	59.3	0.015
Antipsychotics	16.5	16.7	0.8900.290
Antiarrhythmics	8.3	9.7

ACE indicates angiotensin‐converting enzyme; ARBs, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease.

^aProportions and P values 0.05 to 0.001 for χ² tests.

^bProportions and P<0.001 for χ² tests.